{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:30:55Z","timestamp":1790872255791,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,11]]},"DOI":"10.7759\/cureus.108653","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:00:02Z","timestamp":1778508002000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Vericiguat in Heart Failure: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Abdullah","family":"Kilic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayushi","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupanshu","family":"Rupanshu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russaal S","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics\u20142022 update: a report from the American Heart Association","volume":"145","author":"Tsao CW","year":"2022","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, et al.. Heart disease and stroke statistics\u20142022 update: a report from the American Heart Association. Circulation. 2022, 145:e153-639. 10.1161\/CIR.0000000000001052","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2022.02.010","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"28","year":"2022","unstructured":"AHA\/ACC\/HFSA guideline for the management of heart failure. a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Card Fail. 2022, 28:e1-167. 10.1016\/j.cardfail.2022.02.010","journal-title":"J Card Fail"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2021.01.022","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the ESC, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure","volume":"27","author":"Bozkurt B","year":"2021","unstructured":"Bozkurt B, Coats AJ, Tsutsui H, et al.. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the ESC, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021, 27:387-413. 10.1016\/j.cardfail.2021.01.022","journal-title":"J Card Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr254","article-title":"The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis","volume":"33","year":"2012","unstructured":"The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction. an individual patient data meta-analysis. Eur Heart J. 2012, 33:1750-7. 10.1093\/eurheartj\/ehr254","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.12.001","article-title":"Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of galactic-HF","volume":"8","author":"Teerlink JR","year":"2020","unstructured":"Teerlink JR, Diaz R, Felker GM, et al.. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of galactic-HF. JACC Heart Fail. 2020, 8:329-40. 10.1016\/j.jchf.2019.12.001","journal-title":"JACC Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000153349.47314.31","article-title":"Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure","volume":"111","author":"Katz SD","year":"2005","unstructured":"Katz SD, Hryniewicz K, Hriljac I, et al.. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005, 111:310-4. 10.1161\/01.CIR.0000153349.47314.31","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3457","article-title":"Soluble guanylate cyclase stimulators in cardiovascular therapy: an update","volume":"10","author":"Stasch JP","year":"2011","unstructured":"Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase stimulators in cardiovascular therapy: an update. Nat Rev Drug Discov. 2011, 10:724-40. 10.1038\/nrd3457","journal-title":"Nat Rev Drug Discov"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2038","article-title":"NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential","volume":"5","author":"Evgenov OV","year":"2006","unstructured":"Evgenov OV, Pacher P, Schmidt PM, Hask\u00f3 G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006, 5:755-68. 10.1038\/nrd2038","journal-title":"Nat Rev Drug Discov"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction (VICTORIA)","volume":"382","author":"Armstrong PW","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al.. Vericiguat in patients with heart failure and reduced ejection fraction (VICTORIA). N Engl J Med. 2020, 382:1883-93. 10.1056\/NEJMoa1915928","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01665-4","article-title":"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomized trial","volume":"406","author":"Butler J","year":"2025","unstructured":"Butler J, Anstrom KJ, Felker GM, et al.. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomized trial. Lancet. 2025, 406:1341-50. 10.1016\/S0140-6736(25)01665-4","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study","volume":"38","author":"Pieske B","year":"2017","unstructured":"Pieske B, Maggioni AP, Lam CS, et al.. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017, 38:1119-27. 10.1093\/eurheartj\/ehw593","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong PW","year":"2020","unstructured":"Armstrong PW, Lam CS, Anstrom KJ, et al.. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. JAMA. 2020, 324:1512-21. 10.1001\/jama.2020.15922","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt GH","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008, 336:924-6. 10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial","volume":"314","author":"Gheorghiade M","year":"2015","unstructured":"Gheorghiade M, Greene SJ, Butler J, et al.. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 2015, 314:2251-62. 10.1001\/jama.2015.15734","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt G","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, et al.. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011, 64:383-94. 10.1016\/j.jclinepi.2010.04.026","journal-title":"J Clin Epidemiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-Reduced)","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-Reduced). N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01682-4","article-title":"Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials","volume":"406","author":"Zannad F","year":"2025","unstructured":"Zannad F, O'Connor CM, Butler J, et al.. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet. 2025, 406:1351-62. 10.1016\/S0140-6736(25)01682-4","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh TA","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023, 44:3627-39. 10.1093\/eurheartj\/ehad195","journal-title":"Eur Heart J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/452756-efficacy-and-safety-of-vericiguat-in-heart-failure-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:00:03Z","timestamp":1778508003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/452756-efficacy-and-safety-of-vericiguat-in-heart-failure-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.108653","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,11]]}}}